Drug Profile
Research programme: cancer vaccines - Geovax
Alternative Names: GEO CM 01; MUC-1 vaccine; MVA-VLP cancer vaccine - GeoVax Labs; MVA-VLP-MUC1Latest Information Update: 19 Feb 2024
Price :
$50
*
At a glance
- Originator GeoVax Labs
- Developer GeoVax Labs; University of North Carolina at Chapel Hill; University of Pittsburgh
- Class Cancer vaccines; DNA vaccines; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 13 Feb 2024 The Japanese Patent Officeissues a Notice of Allowance for patent application for Cancer vaccines in Japan
- 02 Jan 2024 Preclinical development is ongoing in USA (Parenteral) (GeoVax Labs pipeline, January 2024)
- 16 Nov 2021 MVA VLP MUC1 is still in preclinical trials for Solid tumours (Prevention) in USA (Parenteral)